Drugmaker Teva Pharmaceuticals said it would buy Auspex for $101 per share in cash, or $3.5 billion in equity value.
Teva said the deal, done at a 42 percent premium, would add a portfolio of drugs for the treatment of central nervous system disorders.
Auspex shares closed Friday at $70.91 and had not traded premarket Monday. Teva shares rose 1.5 percent in premarket trading.
Teva said the deal, done at a 42 percent premium, would add a portfolio of drugs for the treatment of central nervous system disorders.
Auspex shares closed Friday at $70.91 and had not traded premarket Monday. Teva shares rose 1.5 percent in premarket trading.
No comments:
Post a Comment